Eli Lilly’s ‘triple G’ drug retatrutide has galvanized the metabolic field to boost investment in the game-changing obesity drug revolution. With up to 24% weight loss, a new record for the obesity field has been set and the time to get ahead of the curve is now. In parallel, we’re witnessing history being made with the world’s first approved NASH treatment potentially being right around the corner with Madrigal’s THR β-selective agonist, marking this year a pivotal time for the metabolic field to forever elevate the approach towards drug development and overcome regulatory barriers.

Reuniting metabolic experts to enable the assessment of the competitive landscape, the 7th Obesity & NASH Drug Development Summit is uniquely positioned to capture all the latest breakthroughs and research you need to join the race and commercialize your GLP-1 RAs, tri-agonists, dual agonists, tetra-specific drugs, glucocorticoid receptor modulators and more.

2023 is an exciting year due to the evolution in digital pathology, artificial intelligence, omics, multifunctional molecules, non-invasive biomarkers, target discovery and liver models, this is your timely meeting dedicated to bringing the metabolic community closer to navigate the route to even more approvals. However, as industry gets closer to successes, challenges remain.

Keen to overcome these discovery, regulatory, clinical, and commercial hurdles?

Join 160+ experts at the largest gathering of obesity and NASH industry drug developers from Eli Lilly, Novo Nordisk, Madrigal, Akero, Gilead, Pfizer, AstraZeneca, Gilead, Inventiva and many more to cultivate sustainable weight-loss drugs and navigate the route towards the first approval in NASH. Don’t miss your opportunity to hear from 42+ metabolic experts over 3 jam-packed days with all the latest end-to-end updates to advance your drug development.

To know more visit: https://bit.ly/465Aa3m